Compare ADPT & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | JBLU |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2019 | 2002 |
| Metric | ADPT | JBLU |
|---|---|---|
| Price | $17.07 | $4.61 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 13 |
| Target Price | ★ $17.78 | $4.91 |
| AVG Volume (30 Days) | 1.7M | ★ 22.9M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | 27.83 |
| EPS | ★ N/A | N/A |
| Revenue | $276,976,000.00 | ★ $9,062,000,000.00 |
| Revenue This Year | $3.98 | $12.11 |
| Revenue Next Year | $22.72 | $6.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $9.96 | $3.87 |
| 52 Week High | $20.76 | $6.46 |
| Indicator | ADPT | JBLU |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 42.56 |
| Support Level | $14.87 | $4.51 |
| Resistance Level | $17.52 | $4.68 |
| Average True Range (ATR) | 0.93 | 0.23 |
| MACD | 0.33 | -0.04 |
| Stochastic Oscillator | 81.33 | 4.08 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.